Skip to main content
. 2021 Sep 24;71(5):1063–1074. doi: 10.1007/s00262-021-03060-w

Fig. 3.

Fig. 3

Kaplan–Meier analysis of overall (a) and progression-free survival (b) after excluding patients with previous targeted therapy (n = 7). ICIs immune checkpoint inhibitors, Len lenvatinib, HR hazard ratio, OS overall survival, PFS progression-free survival